Charles Schwab’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Charles Schwab’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-11,055	Closed	-$209K	–	3166
2016 Q1	$209K	Hold	11,055	–	–	﹤0.01%	2890
2015 Q4	$295K	Hold	11,055	–	–	﹤0.01%	2870
2015 Q3	$505K	Hold	11,055	–	–	﹤0.01%	2622
2015 Q2	$356K	Hold	11,055	–	–	﹤0.01%	2805
2015 Q1	$352K	Hold	11,055	–	–	﹤0.01%	2772
2014 Q4	$418K	Hold	11,055	–	–	﹤0.01%	2695
2014 Q3	$292K	Sell	11,055 -4,500	-29%	-$119K	﹤0.01%	2811
2014 Q2	$461K	Buy	15,555 +3,321	+27%	+$107K	﹤0.01%	2657
2014 Q1	$453K	Buy	12,234 +354	+3%	+$13.4K	﹤0.01%	2623
2013 Q4	$492K	Buy	11,880 +425	+4%	+$16.6K	﹤0.01%	2593
2013 Q3	$605K	Sell	11,455 -8	-0.1%	-$466	﹤0.01%	2473
2013 Q2	$629K	Buy	+11,463	New	+$572K	﹤0.01%	2409

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Charles Schwab's NAVB Position: Q2 2016 in Review

Charles Schwab sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 11,055 shares — an estimated $209K sold.

Charles Schwab first reported a position in NAVB in Q2 2013 and held it in 12 quarters. The position peaked at $629K in Q2 2013. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

Charles Schwab reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
Charles Schwab sold 11,055 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $209K.
Charles Schwab first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 12 quarters.
Charles Schwab's Navidea Biopharmaceuticals Inc. position peaked at $629K in Q2 2013.
63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on Charles Schwab's 13F filing for Q2 2016, filed 15 Aug 2016.